Indaptus Therapeutics develops clinical-stage immunotherapies for cancer and viral infections using its Decoy bacterial platform. The company’s lead candidate, Decoy20, is based on attenuated and killed, non-pathogenic Gram-negative bacteria designed to activate innate and adaptive immune responses, with a focus on solid tumors.
Recurring news for Indaptus covers clinical updates from the INDP-D101 program, including Decoy20 evaluation as monotherapy and in combination with the PD-1 inhibitor tislelizumab. Company updates also include preclinical research on immune-cell activation, quarterly financial results, private placements, convertible notes and warrants, at-the-market financing, reverse stock split actions, Nasdaq compliance matters, and scientific or investor conference presentations.
Indaptus Therapeutics announced that CEO Jeffrey A. Meckler will present at the LD Micro Main Event XV from October 25-27, 2022, at the Luxe Sunset Boulevard Hotel in Los Angeles. The presentation is scheduled for October 25 at 3:30 PM PT (Track 3). Interested parties can register to watch the presentation online. Indaptus focuses on immunotherapy, leveraging patented technology to activate immune responses against tumors and chronic viral infections. The company aims to develop innovative therapies and will hold one-on-one meetings during the conference.
Indaptus Therapeutics (Nasdaq: INDP) announced its CEO, Jeffrey A. Meckler, will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference on September 12, 2022, at 2:00 PM ET. The event will be held at the Lotte New York Palace Hotel from September 12 to 14. A live webcast will be available on the company’s website, with a replay accessible for 90 days after the event. Management will also hold one-on-one meetings post-conference. Details for registration and additional information can be found in the press release.
Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey A. Meckler will present a corporate overview at the JMP Securities Life Sciences Conference on June 16, 2022, at 2:30 p.m. ET in New York City. Investors can access a live webcast of the presentation on the company’s website, with a replay available for 90 days post-event.
Indaptus specializes in immunotherapy, focusing on innovative solutions for cancer and viral infections. Their patented technology aims to activate immune responses through intravenous administration of non-pathogenic bacteria, showing promise in pre-clinical trials for various cancers and chronic viral infections.
Indaptus Therapeutics (Nasdaq: INDP) will present a corporate overview at the Jefferies Healthcare Conference on June 10, 2022, at 12:45 p.m. ET, by CEO Jeffrey A. Meckler. A live webcast will be available on the company's investors section of its website, with a replay accessible for 90 days afterward.
Indaptus specializes in immunotherapy, leveraging patented technology involving non-pathogenic bacteria to activate immune cells for anti-tumor and anti-viral responses. The company has received FDA clearance for a Phase 1 trial of Decoy20 targeting advanced solid tumors.
Indaptus Therapeutics recently announced that the FDA has cleared its IND application for a Phase 1 clinical trial of Decoy20 in patients with advanced solid tumors. Scheduled to start in the second half of 2022, the trial aims to evaluate the safety and preliminary efficacy of Decoy20, which targets tumors resistant to current therapies. Decoy20's unique technology mobilizes both innate and adaptive immune responses without inducing significant side effects. The trial will utilize a dose escalation design, and the therapy could potentially treat various cancers, including pancreatic and colorectal carcinomas.
Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey A. Meckler will present a corporate overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 8:30 AM ET. A live webcast will be available on the company's website and will be archived for 90 days.
Indaptus focuses on immunotherapy, utilizing patented technology that activates innate and adaptive immune cells to combat tumors and viral infections, demonstrating potential in preclinical models against chronic HBV and HIV.
Indaptus Therapeutics has submitted an Investigational New Drug (IND) application for Decoy20, aimed at treating solid tumors, with a Phase 1 clinical trial expected to start in 2022. The submission signifies a crucial step in the development of Decoy20, a dual Toll-like receptor (TLR) agonist that shows promise in activating immune responses against cancers. Financially, the company reported a loss per share of $0.41 for Q1 2022, along with increased R&D and administrative expenses, totaling $3.4 million. Cash reserves decreased to $36.2 million from $39.1 million in Q4 2021.
Indaptus Therapeutics (Nasdaq: INDP) announced that Dr. Michael J. Newman will present at the 2nd Annual Chronic HBV Drug Development Summit from April 25-27, 2022, in Boston, MA. The presentation is titled Driving Pre-Clinical Anti-HBV Activity With a Novel Multi-TLR Agonist Therapeutic Vaccine and will occur on April 27, 2022, at 12:00 PM ET. The summit aims to advance antiviral and immunotherapy development for chronic hepatitis B virus (HBV) treatment.
Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey Meckler will present at the Maxim Group 2022 Virtual Growth Conference on March 28, 2022, at 9:00 a.m. ET. The presentation will be pre-recorded, and an audio webcast will be accessible for 90 days via Indaptus' website. The company focuses on immunotherapy solutions leveraging patented technology involving non-pathogenic bacteria to activate immune responses for anti-tumor and anti-viral applications. Indaptus has successfully manufactured its lead candidate, Decoy20, and has completed various IND enabling studies.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) reported its financial results for Q4 and the year ending December 31, 2021. R&D expenses rose 150% to $1 million for Q4, while total R&D costs decreased 4% to $2.5 million for the year. G&A expenses surged 475% to $2.3 million in Q4, totaling $5.2 million annually, mainly due to payroll and public company costs post-Decoy merger. The company recorded a loss per share of $1.89 and had $39.1 million in cash as of year-end. Net cash used in operating activities ballooned to $11.3 million. Financing activities generated $48.3 million in 2021.